PL2556150T3 - Cząstka wirusowa uwalniana po zakażeniu komórek ssaczych ludzkim cytomegalowirusem (hcmv) zawierająca białko fuzyjne i jej zastosowanie - Google Patents

Cząstka wirusowa uwalniana po zakażeniu komórek ssaczych ludzkim cytomegalowirusem (hcmv) zawierająca białko fuzyjne i jej zastosowanie

Info

Publication number
PL2556150T3
PL2556150T3 PL11713689T PL11713689T PL2556150T3 PL 2556150 T3 PL2556150 T3 PL 2556150T3 PL 11713689 T PL11713689 T PL 11713689T PL 11713689 T PL11713689 T PL 11713689T PL 2556150 T3 PL2556150 T3 PL 2556150T3
Authority
PL
Poland
Prior art keywords
hcmv
infection
fusion protein
mammalian cells
viral particle
Prior art date
Application number
PL11713689T
Other languages
English (en)
Inventor
Sabine Becke
Sabine Reyda
Bodo Plachter
Original Assignee
Vakzine Projekt Management Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vakzine Projekt Management Gmbh filed Critical Vakzine Projekt Management Gmbh
Publication of PL2556150T3 publication Critical patent/PL2556150T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11713689T 2010-04-06 2011-04-06 Cząstka wirusowa uwalniana po zakażeniu komórek ssaczych ludzkim cytomegalowirusem (hcmv) zawierająca białko fuzyjne i jej zastosowanie PL2556150T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10003712 2010-04-06
EP11713689.5A EP2556150B1 (en) 2010-04-06 2011-04-06 Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof

Publications (1)

Publication Number Publication Date
PL2556150T3 true PL2556150T3 (pl) 2017-05-31

Family

ID=43923731

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11713689T PL2556150T3 (pl) 2010-04-06 2011-04-06 Cząstka wirusowa uwalniana po zakażeniu komórek ssaczych ludzkim cytomegalowirusem (hcmv) zawierająca białko fuzyjne i jej zastosowanie

Country Status (25)

Country Link
US (1) US9486517B2 (pl)
EP (1) EP2556150B1 (pl)
JP (1) JP5827312B2 (pl)
KR (2) KR20170108167A (pl)
CN (1) CN102933706B (pl)
AU (1) AU2011238085B2 (pl)
BR (1) BR112012025392B1 (pl)
CA (1) CA2795346C (pl)
CY (1) CY1118138T1 (pl)
DK (1) DK2556150T3 (pl)
ES (1) ES2601850T3 (pl)
HR (1) HRP20161556T1 (pl)
HU (1) HUE030704T2 (pl)
IL (1) IL222229A (pl)
LT (1) LT2556150T (pl)
MX (1) MX2012011639A (pl)
MY (1) MY162335A (pl)
PL (1) PL2556150T3 (pl)
PT (1) PT2556150T (pl)
RS (1) RS55421B1 (pl)
RU (1) RU2623172C2 (pl)
SG (2) SG184261A1 (pl)
SI (1) SI2556150T1 (pl)
SM (2) SMT201700002T1 (pl)
WO (1) WO2011124371A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011101446A1 (de) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
US11986521B2 (en) 2018-06-08 2024-05-21 Vakzine Projekt Management Gmbh Viral particle-based vaccine
EP3587566A1 (en) 2018-06-29 2020-01-01 Bodo Plachter Hcmv vaccine strain
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI871709B (zh) 2020-06-21 2025-02-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白B(gB)多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733540A (en) * 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
WO2006004661A1 (en) 2004-06-25 2006-01-12 Medimmune Vaccines, Inc. Recombinant human cytomegalovirus and vaccines comprising heterologous antigens

Also Published As

Publication number Publication date
IL222229A0 (en) 2012-12-31
BR112012025392B1 (pt) 2021-05-25
KR101839535B1 (ko) 2018-04-27
AU2011238085A1 (en) 2012-10-18
WO2011124371A1 (en) 2011-10-13
EP2556150A1 (en) 2013-02-13
SMT201700002B (it) 2017-03-08
MY162335A (en) 2017-06-15
RU2012146775A (ru) 2014-05-20
MX2012011639A (es) 2012-11-29
JP2013529065A (ja) 2013-07-18
PT2556150T (pt) 2016-11-04
US20130202708A1 (en) 2013-08-08
IL222229A (en) 2017-08-31
ES2601850T3 (es) 2017-02-16
SG184261A1 (en) 2012-10-30
AU2011238085B2 (en) 2016-08-04
CA2795346C (en) 2022-05-03
HUE030704T2 (en) 2017-05-29
CN102933706A (zh) 2013-02-13
US9486517B2 (en) 2016-11-08
RS55421B1 (sr) 2017-04-28
RU2623172C2 (ru) 2017-06-22
HRP20161556T1 (hr) 2016-12-30
CY1118138T1 (el) 2017-06-28
SG10201502271RA (en) 2015-05-28
LT2556150T (lt) 2016-12-12
KR20130055586A (ko) 2013-05-28
CA2795346A1 (en) 2011-10-13
BR112012025392A2 (pt) 2015-09-22
EP2556150B1 (en) 2016-08-24
KR20170108167A (ko) 2017-09-26
SMT201700002T1 (it) 2017-03-08
CN102933706B (zh) 2016-01-13
JP5827312B2 (ja) 2015-12-02
DK2556150T3 (en) 2016-12-05
SI2556150T1 (sl) 2016-12-30

Similar Documents

Publication Publication Date Title
IL222229A0 (en) Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof
IL273107A (en) Pharmacological preparations of human RPE cells and their use
IL251338B (en) Plant cells and extract comprising virus like particles comprising chimeric viral proteins and composition thereof
IL276182A (en) Neutralizing antibodies against the human immunodeficiency virus and methods of using them
SG11201402194RA (en) Cd40l expressing mammalian cells and their use
SG11201405553YA (en) Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
LT2753355T (lt) Onkolitinis herpes simplex virusas ir jo terapinis panaudojimas
IL235323A0 (en) Chimeric proteins to aid in the selection of cells infected with vaccinia virus having a specific recombinant immunoglobulin gene
ZA201404958B (en) Mammalian fetal pulmonary cells and therapeutic use of same
EP2547792A4 (en) PHARMACOGENOMIC TREATMENT AND ADAPTATION TO THE RESPONSE OF AN INFECTIOUS DISEASE USING YEAST IMMUNOTHERAPY
IL221252A (en) Electrolyte system for metal-air batteries and methods for using it
EP2726097A4 (en) HERPES VIRUS VACCINE AND METHOD OF USE
BR112013018845A2 (pt) expressão de glicoproteínas de fusão viral solúveis em células de mamífero
EP2563817A4 (en) FLUORESCENT FUSION POLYPEPTIDES AND METHOD OF USE THEREOF
EP2616073A4 (en) INHIBITORS OF IMMERSION OF VIRUSES IN MAMMALIAN HOST CELLS
IL200187A0 (en) Recombinant antigens of human cytomegalovirus (hcmv)
IL222343B (en) Compositions comprising allogeneic th1 cells and inf-gamma for treating cancer or infectious diseases
GB201218930D0 (en) Parallel charging and discharging of multiple lead acid batteries
HK1183828A (en) Reinforced adhesive complex coacervates and methods of making and using thereof
HK1194758A (en) Autologous human adult pluripotent very small embryonic-like (hvsel) stem cell regeneration of bone and cartilage
HK1191050A (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
HK1197804A (en) Herpes virus vaccine and methods of use